Natalie Missakian

Thermo Fisher Scientific reported “a strong start to the year,” buoyed by strong demand from its pharma and biotech customers, investment in new

German drugmaker Merck KGaA is teaming up with Israeli biotech Remepy to develop so-called hybrid drugs that pair a pharmaceutical with a personalized, AI-driven digital component to enhance the th

Transplant-focused precision medicine company CareDx is making a move into the oncology space, scooping up Massachusetts-based biotech Naveris in a deal worth up to $260 million.

Johnson & Johnson MedTech is touting positive results from the first clinical study of its Ottava soft-tissue surgical robot, showing the system can safely perform gastric bypass surgery.

While GLP-1s like Ozempic and Wegovy are being widely prescribed for weight loss, doctors currently do not have a way to predict if a patient will successfully respond to the drugs.

Scientists know that damage to microscopic blood vessels can provide an early warning sign of heart and kidney disease.

AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year licensing deal with Owkin to leverage its autonomous “AI Scientist” platform.

Fujifilm Healthcare Americas Corp. has signed a deal with Ardent Health to bring its enterprise imaging software to hospitals and clinics in six states.

For Meghan O’Hora, pharma marketing isn’t about patients. It’s about people and making real connections that help them see beyond their diagnosis toward a healthier future.

Tara Sparks was just days away from starting her new job at Novo Nordisk in February 2025 when she gathered with some friends to watch her team, the Philadelphia Eagles, take on reigning Super Bowl